Seres Therapeutics Inc. (MCRB) Sees Unusually-High Trading Volume
Seres Therapeutics Inc. (NASDAQ:MCRB) shares saw unusually-strong trading volume on Friday . Approximately 30,051,027 shares changed hands during mid-day trading, an increase of 1,595% from the previous session’s volume of 1,773,120 shares.The stock last traded at $10.98 and had previously closed at $35.77.
A number of equities research analysts have recently weighed in on MCRB shares. Canaccord Genuity reiterated a “buy” rating on shares of Seres Therapeutics in a research report on Sunday, May 29th. Leerink Swann reiterated a “buy” rating and issued a $43.00 price target on shares of Seres Therapeutics in a research report on Thursday, July 14th. FBR & Co reiterated a “buy” rating on shares of Seres Therapeutics in a research report on Friday, July 8th. Cowen and Company reiterated a “buy” rating on shares of Seres Therapeutics in a research report on Monday, June 13th. Finally, HC Wainwright started coverage on shares of Seres Therapeutics in a research report on Friday. They issued a “buy” rating and a $50.00 price target for the company. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Seres Therapeutics currently has an average rating of “Buy” and an average price target of $43.14.
The company’s 50-day moving average is $30.79 and its 200 day moving average is $28.09. The stock’s market capitalization is $432.34 million.
Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Monday, May 16th. The company reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.02. The firm had revenue of $2.71 million for the quarter, compared to analysts’ expectations of $1.25 million. Analysts anticipate that Seres Therapeutics Inc. will post ($1.81) EPS for the current year.
In other news, major shareholder Ventures Fund 2007 L. Flagship sold 1,000,000 shares of the stock in a transaction that occurred on Wednesday, May 25th. The shares were sold at an average price of $27.60, for a total transaction of $27,600,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Michele Trucksis sold 4,156 shares of the stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $35.18, for a total transaction of $146,208.08. Following the transaction, the insider now directly owns 4,156 shares of the company’s stock, valued at $146,208.08. The disclosure for this sale can be found here.
Several hedge funds and institutional investors recently added to or reduced their stakes in MCRB. ProShare Advisors LLC bought a new position in Seres Therapeutics during the fourth quarter worth $1,146,000. Morgan Stanley increased its position in Seres Therapeutics by 225.3% in the fourth quarter. Morgan Stanley now owns 33,758 shares of the company’s stock worth $1,185,000 after buying an additional 23,381 shares in the last quarter. BlackRock Advisors LLC increased its position in Seres Therapeutics by 0.7% in the fourth quarter. BlackRock Advisors LLC now owns 340,871 shares of the company’s stock worth $11,962,000 after buying an additional 2,443 shares in the last quarter. Finally, Jennison Associates LLC increased its position in Seres Therapeutics by 1.9% in the fourth quarter. Jennison Associates LLC now owns 398,959 shares of the company’s stock worth $13,999,000 after buying an additional 7,259 shares in the last quarter.
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.